Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence

Rheumatology International

Volumn 36, Issue 7, 2016, Pages 987-995

  Dalén, Johan ^a   Svedbom, Axel ^a,b   Black, Christopher M ^c   Lyu, Ramon ^c   Ding, Qian ^c   Sajjan, Shiva ^c   Sazonov, Vasilisa ^d   Kachroo, Sumesh ^c  

^a MAPI GROUP   (Netherlands)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MERCK RESEARCH LABORATORIES   (United States)

^d MSD Inovativna Zdravilla   (Slovenia)

Author keywords

Ankylosing spondylitis; Biologics; Immune mediated rheumatic disease; Persistence; Psoriatic arthritis; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MEDICATION COMPLIANCE; OUTPATIENT CARE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; AGED; ANTAGONISTS AND INHIBITORS; COST BENEFIT ANALYSIS; COST CONTROL; DRUG ADMINISTRATION; DRUG COST; ECONOMICS; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; PRESCRIPTION; REGISTER; RHEUMATIC DISEASES; SWEDEN; TIME FACTOR; TREATMENT OUTCOME;

ADALIMUMAB; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOLOGICAL PRODUCTS; CERTOLIZUMAB PEGOL; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG PRESCRIPTIONS; ETANERCEPT; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; SWEDEN; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84954428844     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-016-3423-5     Document Type: Article

References (21)

1. Blum MA, Koo D, Doshi JA (2011) Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther 33(7):901–913
2. Tang B et al (2008) Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther 30(7):1375–1384
3. Baser O, Ganguli A, Roy S, Xie L, Cifaldi M (2015) Impact of switching from an initial tumor necrosis factor inhibitor on health care resource utilization and costs among patients with rheumatoid arthritis. Clin Ther 37(7):1454–1465. doi:10.1016/j.clinthera.2015.04.012
4. Meissner B et al (2014) Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting. J Med Econ 17(4):259–265
5. Kodningskvalitet i patientregistret. The National Board of Health and Welfare (Socialstyrelsen). http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/18082/2010-6-27.pdf. Accessed 23 June 2015
6. Causes of Death 2013. The National Board of Health and Welfare (Socialstyrelsen). https://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/19736/2015-2-42.pdf. Accessed 20 Aug 2015
7. Pharmaceuticals—statistics for 2014. The National Board of Health and Welfare (Socialstyrelsen). https://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/19768/2015-3-17.pdf. Accessed 20 Aug 2015
8. Cramer JA et al (2008) Medication compliance and persistence: terminology and definitions. Value Health 11(1):44–47
9. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
10. D’Agostino RB Jr (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17(19):2265–2281
11. Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70(1):41–55
12. Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28(25):3083–3107
13. Ho DE (2007) Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Polit Anal 15(3):199–236
14. Imai K, King G, Stuart EA (2008) Misunderstandings between experimentalists and observationalists about causal inference. J R Stat Soc Series A 171(Part 2):481–502
15. Rosenbaum PR, Rubin DB (1985) Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 39(1):33–38
16. Wu E, Chen L, Birnbaum H et al (2008) Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with RA. Curr Med Res Opin 24:2229–2240
17. Khalil H, Tahami A (2012) Golimumab drug utilization patterns in Canada—higher retention rate in golimumab treated rheumatoid patients arthritis patients compared to etanercept and adalimumab [Abstract]. Arthritis Rheum 64(Suppl 10):497. doi:10.1002/art.38232
18. Svedbom A et al (2015) Treatment patterns with topicals, traditional systemics and biologics in psoriasis—a Swedish database analysis. J Eur Acad Dermatol Venereol 29(2):215–223
19. Neovius M et al (2015) Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis 74(2):354–360
20. Chatzidionysiou K, Kristensen LE, Eriksson J, Askling J, van Vollenhoven R, For The Artis G (2015) Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register. Scand J Rheumatol 44(6):431–437. doi:10.3109/03009742.2015.1026840
21. Saevarsdottir S, Santacatterina M, Stawiarz L, Turesson C, Forsblad H, Jacobsson LTH, Lindblad S (2013) Drug survival in patients receiving Golimumab treatment 2010–2013. Results from the Swedish Rheumatology Quality Register [abstract]. Arthritis Rheum 65(Suppl 10):1514. doi:10.1002/art.2013.65.issue-s10